Premium
Clinical predictors of SARS‐CoV‐2 neutralizing antibody titers in COVID‐19 convalescents: Implications for convalescent plasma donor recruitment
Author(s) -
Focosi Daniele,
Franchini Massimo
Publication year - 2021
Publication title -
european journal of haematology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.904
H-Index - 84
eISSN - 1600-0609
pISSN - 0902-4441
DOI - 10.1111/ejh.13630
Subject(s) - convalescent plasma , titer , medicine , serology , covid-19 , neutralizing antibody , virology , population , immunology , clinical trial , antibody , antibody titer , disease , environmental health , infectious disease (medical specialty)
While COVID‐19 convalescent plasma (CCP) efficacy is still under investigation in randomized controlled trials (RCT), CCP collections continue worldwide with largely variable criteria. Since it is well known that only a minority of patients develop high‐titer neutralizing antibodies (nAb), as assessed by the viral neutralization tests (VNT), strategies to maximize cost‐effectiveness of CCP collection are urgently needed. A growing amount of the population is having exposure to the virus and is hence becoming a candidate CCP donor. Laboratory screening with high‐throughput serology has good correlations with the VNT titer, but upstream screening using clinical surrogates would be advisable. We review here the existing literature on clinical predictors of high‐titer nAb. Older age, male sex, and hospitalization are the main proxies of high VNT and should drive CCP donor recruitment.